IMMUTEP Ltd
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
other
SEC Category
Accelerated filer
State of Incorporation
Australia
Business Address
LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE, SYDNEY,, C3, NSW 2000
Mailing Address
LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE, SYDNEY,, C3, NSW 2000
Phone
612 8315 7003
Fiscal Year End
0630
EIN
000000000
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 3 Initial insider ownership report | April 1, 2026 | View on SEC |
| 3 Initial insider ownership report | April 1, 2026 | View on SEC |
| 3 Initial insider ownership report | April 1, 2026 | View on SEC |
| 3 Initial insider ownership report | April 1, 2026 | View on SEC |
| 6-K Foreign company current report | March 20, 2026 | View on SEC |
| 6-K Foreign company current report | March 16, 2026 | View on SEC |
| 6-K Foreign company current report | February 26, 2026 | View on SEC |
| 6-K Foreign company current report | February 10, 2026 | View on SEC |
| 6-K Foreign company current report | January 30, 2026 | View on SEC |
| 6-K Foreign company current report | December 23, 2025 | View on SEC |
Annual Reports
20-F
October 24, 2025
- Positive early results in lung and breast cancer trials
- Partnered with Ridgeback Capital for funding and expertise
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.